Augmentation of antitumor effect of endogenously induced tumor necrosis factor by cyclophosphamide

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 55-60

  Inagawa, Hiroyuki ^a   Ohshiro, Shinya ^b   Nishizawa, Takashi ^a   Goto, Shigenori ^c   Soma, Gen Ichiro ^a,d   Mizuno, Den'Ichi ^e  

^a TAKANO HOSPITAL   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c Kitatama Hospital   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

Antitumor therapy; Cyclophosphamide; Endogenous tumor necrosis factor

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; GAMMA INTERFERON; MITOMYCIN C; PICIBANIL; PUROMYCIN; TEGAFUR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME; TUMOR MODEL; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031059409     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Satoh M, Inagawa H, Minagawa H, et al: Endogenous production of TNF in mice long after BCG sensitization. J Biol Resp Modif 5: 117-123, 1986.
2. Satoh M, Inagawa H, Minagawa H, et al: Endogenous production of TNF in mice with immune complex as a primer. J Biol Resp Modif 5: 140-147, 1986.
3. Saton M, Inagawa H, Shimada Y, et al: Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin. J Biol Resp Modif 6: 512-524, 1987.
4. Inagawa H, Oshima H, Soma G-I, et al: TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of recombinant TNF together with endogenous TNF. J Biol Resp Modif 7:596-607, 1988.
5. Okutomi T, Inagawa H, Nishizawa T, et al: Priming effect of orally administered muramyl dipeptide on induction of endogenous tumor necrosis factor. J Biol Resp Modif 9: 564-569, 1990.
6. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
7. Kato M, Kakehi R, Soma G-I, et al: Anti-tumor therapy by induction of endogenous tumor necrosis factor. Lancet ii: 270 1985.
8. Takagi K, Fujiyoshi T, Takano M, et al: Endogenous and exogenous TNF therapy (EET therapy) to metastatic lesions in liver and local recurrent lesions of colorectal carcinoma. Immunobiology 175 1/2: 57-58, 1987.
9. Dobashi K, Takeshita S, Tsujii T, et al: Endogenous and exogenous TNF therapy (EET therapy) as a novel anti-tumor approach: clinical efficacy on gynecologic tumors. Immunobiology 75 1/2: 93-94, 1987.
10. Nishizawa T, Okutomi T, Inagawa H, et al: Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous/ endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers. Mol Biother 3: 224-230, 1991.
11. Bersani L, Colotta F and Mantovani A: Involvement of tumor necrosis factor in monocyte-mediated rapid killing of actinomycin D- treated WHEI-164 sarcoma cells. Immunology 53: 323, 1986.
12. Haranaka K, Satomi N and Sakurai A: Antitumor activity of recombinant tumor necrosis factor in combination with hyperthermia, chemotherapy or immunotherapy. J Biol Resp Modif 6: 379-391, 1987.
13. Ehrke MJ, Yerstovsek S, Krawczyk CM et al: Cyclophosphamide plus tumor neciosis factor-α chemo-immunotherupy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer 63: 463-471, 1995.
14. Ohshiro S, Inagawa H, Soma GI, et al: Antitumor effect of exogenous/endogenous TNF (EET) therapy with cyclophosphamide on C6 glioma in rat. Cancer Biother 9: 359-367, 1994.
15. Soma G-I, Tsuji Y, Tanabe Y, et al: Biological activities of novel recombinant tumor necrosis factor having N-torminal amino acid sequences derived from cytotoxic factors by THP-1 cells. J Biol Resp Modif 7: 587-595, 1988.
16. Shen R-N, Wu B, Lu L, et al: Recombinant human interleukin-1 alpha: a potent bio-immunomodifier in vivo in immune-suppressed mice induced by cyclophosphamide, retroviral infection and surgical stress. In Vivo 8: 59-64, 1994.
17. Awwad M and North RJ: Cyclophosphamide-induced immunologically mediated regression of a cycluphosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T- cells. Cancer Res 49: 1649-1654, 1989.
18. Gorelik L, Rubin M, Prokhorova A, et al: Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J Immunol 154: 3941-3951, 1995.
19. Manusama ER, Nooijen PTGA, Stavast J, et al: Synergistic antitumor effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat, Br J Surgery 83: 551-555, 1996.
20. Lejeune FJ: High dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion of advanced tumors of the limbs: a model for biochemotherapy of cancer. Eur J Cancer 31A: 1009-1016, 1995.
21. Goto S, Kera J, Suma Y, et al: Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunology Immunotherapy 42: 255-261, 1996.